Leiden, The Netherlands, September 20, 2001 - Crucell N.V. (NASDAQ: CRXL; Euronext Amsterdam: CRXL), today announced that it has appointed Dr Jaap Goudsmit as Senior Vice President Vaccine Research. Dr Goudsmit will head Crucell's vaccine research program.

Prior to joining Crucell, Dr Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, most recently holding the titles of chairman of the Research Institute for Infectious Diseases and the Institute for Science Education.
Furthermore, Dr Goudsmit has been appointed chairman to several national and international committees. Dr Goudsmit is co-founder of both IAVI (International AIDS Vaccine Initiative), the premier non-governmental driving force for a global HIV vaccine, and EuroVac, the European Union AIDS vaccine effort to bring promising vaccine concepts to human testing. Dr Goudsmit is currently chair of the Scientific Advisory Committee of IAVI and co-chair of EuroVac.

Dr Goudsmit has authored over 450 publications and been a reviewer for a number of leading peer-reviewed journals. He is a board certified medical microbiologist and since 1989 full professor of virology at the University of Amsterdam. Dr Goudsmit has taught and been a fellow at a number of institutions, such as the National Institutes of Health and New York University. He received a PhD in virology from the University of Amsterdam and a medical degree from the Faculty of Medicine of the University of Amsterdam. Dr Goudsmit remains affiliated with the University of Amsterdam and the Amsterdam Medical Center as professor of virology.

"Crucell's breakthrough technologies allows the understanding of the mechanisms of diseases and the development of revolutionary tools to design drugs," said Dr Jaap Goudsmit. "Crucell provides the ideal
environment for addressing the challenges of vaccine development and I am very excited to expand and develop the vaccine programs of such an entrepreneurial and innovative organization."

"Dr Goudsmit joins Crucell with outstanding achievements in the field of virology," said Ton Logtenberg, CSO of Crucell. "Our organization's future growth is dependent on attracting such talents with outstanding skills and unique experience bases."

About Crucell
Crucell, a leading biotechnology company, discovers and develops biopharmaceutical products that utilize the immune system to combat disease. Crucell's human technology platforms, MAbstractTM and PER.C6TM, are applicable for discovery and development of antibody and vaccine products. Crucell's MAbstractTM discovery and development programs are focused on human antibody-based therapeutics for treatment of cancer and inflammatory diseases. Crucell's vaccine programs are focused on the prevention and treatment of influenza and other infectious diseases.
Crucell enters into licensing or co-development agreements for its in-house products, or starts new target discovery and product development programs with partners.
Currently, Crucell has five fully human antibodies in various stages of pre-clinical development for the treatment of colon cancer, breast cancer, anti-angiogenesis, leukemia and inflammation. Additional programs have been launched in oncology, diabetes and cardiovascular diseases. In August 2001, the company entered into an agreement with Centocor, Inc., for the development and commercialization of its CD46-specific human antibodies for the treatment of cancer.
Crucell's PER.C6(TM) fully human production cell line technologies are made available under license agreements for antibodies, proteins, vaccines and vector technology applications. Crucell has currently signed 18 PER.C6(TM) agreements with major pharmaceutical and biotechnology companies.
Crucell has a listing on NASDAQ and Euronext, and has raised EUR 144 million in its October 2000 IPO. Crucell currently employs approximately 140 people in its facilities in Leiden and Utrecht.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. See our Registration Statement, as filed on Form F-1 with the U.S. Securities and Exchange Commission on October 26, 2000, (the "Registration Statement") and the section of the Registration Statement entitled "Risk Factors".

http://reports.huginonline.com/834526/94633.pdf

Please click on the link to view the formatted version of the press release. If you have any queries or questions please contact Noonan/Russo on +44 (0)207 726 5542